Anti-β2-glycoprotein I antibodies in children with atopic dermatitis

Aleš Ambrožiž, Tadej Avičin, Kenji Ichikawa, Tanja Kveder, Eiji Matsuura, Maja Hojnik, Tatsuya Atsumi, Blaž Rozman, Takao Koike

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

β2-Glycoprotein I (β2GPI) appears to be the major antigen for antiphospholipid antibodies (aPL) in patients with antiphospholipid syndrome (APS). In early infancy, virtually all children initiate transient immune response to non-pathogenic nutritional antigens, which fails to terminate in children with atopic diseases. To examine the possibility that a prolonged immune response to β2GPI could also spread to the human protein, antibodies against human β2GPI (anti-β2GPI) were determined in 93 randomly selected children with different allergic diseases. A high frequency (42%) of IgG anti-β2GPI was found in children with atopic dermatitis (AD), but not in those with other allergic diseases. Anti-β2GPI in children with AD were exclusively of the IgG1 subclass and bound to bovine β2GPI as well, but not to either β2GPI combined with the phospholipid cardiolipin. The epitopes were identified in domain V of β2GPI and the antibody binding was abolished upon the specific proteolytic cleavage of the phospholipid-binding C-terminal loop in domain V of β2GPI. These results indicated that the epitopes for anti-β2GPI in children with AD most likely resided in close vicinity of the phospholipid-binding site of β2GPI. The epitopic difference from anti-β2GPI in APS may explain presumed non-thrombogenicity of anti-β2GPI in children with AD.

Original languageEnglish
Pages (from-to)823-830
Number of pages8
JournalInternational Immunology
Volume14
Issue number7
Publication statusPublished - 2002

Fingerprint

Atopic Dermatitis
Glycoproteins
Antibodies
Phospholipids
Antiphospholipid Syndrome
Epitopes
Immunoglobulin G
Antigens
Antiphospholipid Antibodies
Cardiolipins
Binding Sites

Keywords

  • Allergy
  • Antigen
  • Antiphospholipid antibody
  • Autoantibody
  • Autoimmunity
  • Epitope

ASJC Scopus subject areas

  • Immunology

Cite this

Ambrožiž, A., Avičin, T., Ichikawa, K., Kveder, T., Matsuura, E., Hojnik, M., ... Koike, T. (2002). Anti-β2-glycoprotein I antibodies in children with atopic dermatitis. International Immunology, 14(7), 823-830.

Anti-β2-glycoprotein I antibodies in children with atopic dermatitis. / Ambrožiž, Aleš; Avičin, Tadej; Ichikawa, Kenji; Kveder, Tanja; Matsuura, Eiji; Hojnik, Maja; Atsumi, Tatsuya; Rozman, Blaž; Koike, Takao.

In: International Immunology, Vol. 14, No. 7, 2002, p. 823-830.

Research output: Contribution to journalArticle

Ambrožiž, A, Avičin, T, Ichikawa, K, Kveder, T, Matsuura, E, Hojnik, M, Atsumi, T, Rozman, B & Koike, T 2002, 'Anti-β2-glycoprotein I antibodies in children with atopic dermatitis', International Immunology, vol. 14, no. 7, pp. 823-830.
Ambrožiž A, Avičin T, Ichikawa K, Kveder T, Matsuura E, Hojnik M et al. Anti-β2-glycoprotein I antibodies in children with atopic dermatitis. International Immunology. 2002;14(7):823-830.
Ambrožiž, Aleš ; Avičin, Tadej ; Ichikawa, Kenji ; Kveder, Tanja ; Matsuura, Eiji ; Hojnik, Maja ; Atsumi, Tatsuya ; Rozman, Blaž ; Koike, Takao. / Anti-β2-glycoprotein I antibodies in children with atopic dermatitis. In: International Immunology. 2002 ; Vol. 14, No. 7. pp. 823-830.
@article{efd9bd7416784026a9850e92e624b541,
title = "Anti-β2-glycoprotein I antibodies in children with atopic dermatitis",
abstract = "β2-Glycoprotein I (β2GPI) appears to be the major antigen for antiphospholipid antibodies (aPL) in patients with antiphospholipid syndrome (APS). In early infancy, virtually all children initiate transient immune response to non-pathogenic nutritional antigens, which fails to terminate in children with atopic diseases. To examine the possibility that a prolonged immune response to β2GPI could also spread to the human protein, antibodies against human β2GPI (anti-β2GPI) were determined in 93 randomly selected children with different allergic diseases. A high frequency (42{\%}) of IgG anti-β2GPI was found in children with atopic dermatitis (AD), but not in those with other allergic diseases. Anti-β2GPI in children with AD were exclusively of the IgG1 subclass and bound to bovine β2GPI as well, but not to either β2GPI combined with the phospholipid cardiolipin. The epitopes were identified in domain V of β2GPI and the antibody binding was abolished upon the specific proteolytic cleavage of the phospholipid-binding C-terminal loop in domain V of β2GPI. These results indicated that the epitopes for anti-β2GPI in children with AD most likely resided in close vicinity of the phospholipid-binding site of β2GPI. The epitopic difference from anti-β2GPI in APS may explain presumed non-thrombogenicity of anti-β2GPI in children with AD.",
keywords = "Allergy, Antigen, Antiphospholipid antibody, Autoantibody, Autoimmunity, Epitope",
author = "Aleš Ambrožiž and Tadej Avičin and Kenji Ichikawa and Tanja Kveder and Eiji Matsuura and Maja Hojnik and Tatsuya Atsumi and Blaž Rozman and Takao Koike",
year = "2002",
language = "English",
volume = "14",
pages = "823--830",
journal = "International Immunology",
issn = "0953-8178",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Anti-β2-glycoprotein I antibodies in children with atopic dermatitis

AU - Ambrožiž, Aleš

AU - Avičin, Tadej

AU - Ichikawa, Kenji

AU - Kveder, Tanja

AU - Matsuura, Eiji

AU - Hojnik, Maja

AU - Atsumi, Tatsuya

AU - Rozman, Blaž

AU - Koike, Takao

PY - 2002

Y1 - 2002

N2 - β2-Glycoprotein I (β2GPI) appears to be the major antigen for antiphospholipid antibodies (aPL) in patients with antiphospholipid syndrome (APS). In early infancy, virtually all children initiate transient immune response to non-pathogenic nutritional antigens, which fails to terminate in children with atopic diseases. To examine the possibility that a prolonged immune response to β2GPI could also spread to the human protein, antibodies against human β2GPI (anti-β2GPI) were determined in 93 randomly selected children with different allergic diseases. A high frequency (42%) of IgG anti-β2GPI was found in children with atopic dermatitis (AD), but not in those with other allergic diseases. Anti-β2GPI in children with AD were exclusively of the IgG1 subclass and bound to bovine β2GPI as well, but not to either β2GPI combined with the phospholipid cardiolipin. The epitopes were identified in domain V of β2GPI and the antibody binding was abolished upon the specific proteolytic cleavage of the phospholipid-binding C-terminal loop in domain V of β2GPI. These results indicated that the epitopes for anti-β2GPI in children with AD most likely resided in close vicinity of the phospholipid-binding site of β2GPI. The epitopic difference from anti-β2GPI in APS may explain presumed non-thrombogenicity of anti-β2GPI in children with AD.

AB - β2-Glycoprotein I (β2GPI) appears to be the major antigen for antiphospholipid antibodies (aPL) in patients with antiphospholipid syndrome (APS). In early infancy, virtually all children initiate transient immune response to non-pathogenic nutritional antigens, which fails to terminate in children with atopic diseases. To examine the possibility that a prolonged immune response to β2GPI could also spread to the human protein, antibodies against human β2GPI (anti-β2GPI) were determined in 93 randomly selected children with different allergic diseases. A high frequency (42%) of IgG anti-β2GPI was found in children with atopic dermatitis (AD), but not in those with other allergic diseases. Anti-β2GPI in children with AD were exclusively of the IgG1 subclass and bound to bovine β2GPI as well, but not to either β2GPI combined with the phospholipid cardiolipin. The epitopes were identified in domain V of β2GPI and the antibody binding was abolished upon the specific proteolytic cleavage of the phospholipid-binding C-terminal loop in domain V of β2GPI. These results indicated that the epitopes for anti-β2GPI in children with AD most likely resided in close vicinity of the phospholipid-binding site of β2GPI. The epitopic difference from anti-β2GPI in APS may explain presumed non-thrombogenicity of anti-β2GPI in children with AD.

KW - Allergy

KW - Antigen

KW - Antiphospholipid antibody

KW - Autoantibody

KW - Autoimmunity

KW - Epitope

UR - http://www.scopus.com/inward/record.url?scp=0036315878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036315878&partnerID=8YFLogxK

M3 - Article

C2 - 12096042

AN - SCOPUS:0036315878

VL - 14

SP - 823

EP - 830

JO - International Immunology

JF - International Immunology

SN - 0953-8178

IS - 7

ER -